Recent studies in dog models of NCL suggest that multiple intracranial treatments of rhTPP1 could offer dramatic improvements (122), and a recombinant PPT1 proenzyme treatment has proved promising in CLN1 disease mouse models (124). This evidence concerns the gene PPT1 and neuronal ceroid lipofuscinosis.